AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q110631

Application No.: 10/650,931

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

(Currently amended): A sustained-release composition for oral administration of

a drug selected from the group consisting of nifedipine and lovastatin, comprising the drug, a

carrier for sustained release of the drug and a gel hydration accelerator, said composition being

delivered to the gastrointestinal tract where the drug is released at a constant rate following zero

order kinetics over a period of 24 hours or more,

wherein the weight ratio of the drug: the carrier for sustained release of the drug: the gel

hydration accelerator is in the range of 1:3 to 30:0.1 to 15; the carrier is a mixture of sodium

alginate and xanthan gum having a weight ratio of 1:1 to 10; and the gel hydration accelerator is

a mixture of hydroxypropyl methylcellulose and propylene glycol alginate having a weight ratio

of 1:0.05 to 20.

6.

2 - 4. (Canceled).

(Previously presented):

The composition of claim 1, wherein the carrier

further comprises locust bean gum.

(Previously presented):

The composition of claim 5, wherein the weight

ratio of sodium alginate: xanthan gum: locust bean gum is in the range of 1: 0.2 to 10: 0.1 to 5.

(Canceled).

(Previously presented):

The composition of claim 1, wherein the drug is

selected from the group consisting of antihypertensive drugs, drugs for cardiovascular diseases,

2

AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q110631

Application No.: 10/650,931

drugs for hyperlipemia, non-steroidal anti-inflammatory drugs, drugs for asthma, anti-diabetes drugs, calmative, antibiotics, antispasmodic steroids and a mixture thereof.

9. (Canceled).

10. (Currently amended): A sustained-release composition for oral administration of a drug selected from the group consisting of nifedipine, isradipine, and lovastatin-and-glipizide, comprising the drug, a mixture of sodium alginate and xanthan gum, and a mixture of hydroxypropyl methylcellulose and propylene glycol alginate,

wherein the weight ratio of the drug: the mixture of sodium alginate and xanthan gum: the mixture of hydroxypropyl methylcellulose and propylene glycol alginate is in the range of 1:3 to 30: 0.1 to 15; sodium alginate and xanthan gum have a weight ratio of 1:0.1 to 10; and hydroxypropyl methylcellulose and propylene glycol alginate have a weight ratio of 1:0.05 to 20.